Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe Europe - 07/19 05:30:00 pm
80.88 CHF   +0.27%
02:37pNovartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
11:55aBarclays appoints Campili as vice chairman for healthcare banking
RE
08:48aNOVARTIS : Freezes Its Drug Prices -- WSJ
DJ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Most relevant news about NOVARTIS
02:37pNovartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
11:55aBarclays appoints Campili as vice chairman for healthcare banking
RE
08:48aNOVARTIS : Freezes Its Drug Prices -- WSJ
DJ
07:16aNOVARTIS : demonstrates commitment to lead immuno-dermatology by in-licensing IL..
GL
03:54aNOVARTIS : FDA Oks Novartis' Kisqali For Use In Pre/Perimenopausal Women With Br..
AQ
07/18Novartis hints at 2018 outlook hike despite drug price freeze
RE
07/18Novartis hints at 2018 outlook hike despite drug price freeze
RE
07/18NOVARTIS : FDA Expands Approval of Novartis Breast Cancer Drug
DJ
07/18NOVARTIS : Kisqali® now first and only CDK4/6 inhibitor indicated in US as first..
GL
07/18NOVARTIS : to Refrain From Rising U.S. Drug Prices -- 3rd Update
DJ
07/18NOVARTIS : to Refrain From Raising U.S. Drug Prices -- 2nd Update
DJ
07/18NOVARTIS : to Refrain From Raising U.S. Drug Prices -- Update
DJ
07/18NOVARTIS : 2Q Earnings Snapshot
AQ
07/18NOVARTIS : Backs 2018 Outlook, Says Cohen Affair Is 'Closed' -- Update
DJ
07/18NOVARTIS : Backs 2018 Outlook After Sales Grow
DJ
More most relevant news
All news about NOVARTIS
02:37pNovartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
01:45pNOVARTIS : Kisqali Now First and Only CDK4/6 Inhibitor Indicated in US as First-..
AQ
11:55aBarclays appoints Campili as vice chairman for healthcare banking
RE
08:48aNOVARTIS : Freezes Its Drug Prices -- WSJ
DJ
07:16aNOVARTIS : demonstrates commitment to lead immuno-dermatology by in-licensing IL..
GL
03:54aNOVARTIS : FDA Oks Novartis' Kisqali For Use In Pre/Perimenopausal Women With Br..
AQ
07/18Novartis hints at 2018 outlook hike despite drug price freeze
RE
07/18Novartis hints at 2018 outlook hike despite drug price freeze
RE
07/18NOVARTIS : FDA Expands Approval of Novartis Breast Cancer Drug
DJ
07/18NOVARTIS : Kisqali® now first and only CDK4/6 inhibitor indicated in US as first..
GL
More news
Sector news : Pharmaceuticals - NEC
03:19pBarclays Poaches Senior Health-Care Banker From Deutsche Bank
DJ
12:19pFinance Chiefs Say Too Much Data Is Making It Harder to Keep on Top of Risks
DJ
11:55aBarclays appoints Campili as vice chairman for healthcare banking
RE
08:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07/18Novartis hints at 2018 outlook hike despite drug price freeze
RE
07/18Novartis hints at 2018 outlook hike despite drug price freeze
RE
More sector news : Pharmaceuticals - NEC
Official Publications
03/02Press Release 
03/02Proxy Statments 
01/24Annual results 
01/24Slide show results 
2017Annual Report 
2017Slide show Q3 results 
More official Publications
News from SeekingAlpha
08:39aGalapagos and MorphoSys out-license MOR106 to Novartis for up to $1.1B 
07:35aAmazon Tops $900 Billion In Market Value (Wall Street Breakfast Podcast) 
07:01aWALL STREET BREAKFAST : Race To $1T Market Cap 
07/18FDA committed to easing approval path for biosimilars 
07/18Novartis AG 2018 Q2 - Results - Earnings Call Slides 
07/18Novartis AG (NVS) CEO Vasant Narasimhan on Q2 2018 Results - Earnings Call Tr.. 
Latest Tweets
04:11pNovartis pays €95M to bag dermatitis drug from Galapagos, MorphoSys  
04:10pRoche takes Tecentriq hit on survival data
3
03:42pMorphoSys and Galapagos will remain involved in the clinical development of M.. 
03:25pBenzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debu.. 
03:13pNovartis $NVS Stock Rating Upgraded by Barclays  
More tweets
Qtime:353
Financials ($)
Sales 2018 51 717 M
EBIT 2018 12 547 M
Net income 2018 9 631 M
Debt 2018 13 552 M
Yield 2018 3,64%
P/E ratio 2018 16,48
P/E ratio 2019 20,19
EV / Sales 2018 4,13x
EV / Sales 2019 3,98x
Capitalization 200 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 89,7 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-2.11%200 139
JOHNSON & JOHNSON-7.59%346 292
PFIZER3.95%220 236
ROCHE HOLDING LTD.-4.77%200 995
MERCK AND COMPANY11.85%168 225
AMGEN10.87%128 318